DZDarren M. Zuro

Darren M. Zuro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Darren M. Zuro has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AML ImmunoPET: 64 Cu-DOTA-anti-CD33 PET-CT imaging of AML in Xenograft mouse model

    by Srideshikan Sargur Madabushi, Jamison L Brooks, Darren Zuro, Bijender Kumar, James Sanchez, Liliana Echavarria Parra, Marvin Orellana, Paresh Vishwasrao, Indu Nair, Junie Chea, et al.

    Purpose: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia that results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is currently no AML-specific non-invasive imaging method to assess disease in the whole body, including in extramedullary organs, representing an unmet clinical need. About 85-90% of human myeloid leukemia cells express CD33 (an accepted biomarker for AML) cell surface receptors, highlighting CD33 as an ideal candidate for AML immunoPET. Experimental Design: In this study, we evaluated if 64 Cu-DOTA-anti-CD33 murine monoclonal antibody (mAb) can be used for ImmunoPET-CT imaging of AML in preclinical model. For translational purpose, a humanized anti-CD33 antibody was produced, and after confirming its anti-CD33 PET-CT imaging ability we further explored its therapeutic potential. Results: 64 Cu-DOTA-anti-CD33 based PET-CT imaging detected CD33 + AML in mice with high sensitivity (95.65%) and specificity (100%). In the entire skeletal system, CD33 + PET activity was significantly high in the bones of AML bearing mice over non-leukemic control mice; femur (p+ PET activity prevelant in epiphysis/diaphysis of the bones, indicating spatial heterogeneity. Anti-CD33 therapy using newly developed humanized anti-CD33 mAb as an ADC (p=0.02) and 225 Ac-anti-CD33-RIT (p64 Cu-DOTA-anti-CD33), a CD33 PET-CT imaging modality was developed that detected AML with high sensitivity and specificity. The approach also indicated spatial heterogeneity in leukemic disease, dependent on disease burden, which warrants caution in analyzing results from single point bone marrow biopsies. Therefore, this imaging modality can be used to non-invasively detect AML in humans and also monitor treatment response, an unmet clinical need.

  • Open Access

    Development of Kinetic Modeling to Assess Multi-functional Vascular Response to Low Dose Radiation in Leukemia

    by Jamison Brooks, Bijender Kumar, Darren M. Zuro, Jonathon D. Raybuck, Srideshikan Sargur Madabushi, Paresh Vishwasrao, Liliana Echavarria Parra, Marcin Kortylewski, Brian Armstrong, Susanta K Hui

    Vascular permeability, tissue transfer rate (K trans ), fractional extracellular tissue space (ν ec ) and blood perfusion are crucial parameters to assess bone marrow vasculature (BMV) function. However, quantitative measurements of these parameters in a mouse model are difficult because of limited resolution of standard macroscopic imaging modalities. Using intravital multiphoton microscopy (MPM), live imaging of dextran transfer from BMV to calvarium tissue of mice bearing acute lymphoblastic leukemia (ALL) was performed to obtain BMV parameters. Mice bearing ALL had increased BMV permeability, altered K trans , increased ν ec , decreased blood perfusion, and increased BMV permeability resulting in reduced drug uptake. Targeted 2 Gy radiation therapy (RT) to mice bearing ALL increased local BMV perfusion and ALL chemotherapy uptake (P<0.0001 and P=0.0036, respectively), suggesting RT prior to chemotherapy treatment may increase treatment efficacy. Developed MPM techniques allow for a quantitative assessment of BMV functional parameters not previously performed with microscopic or macroscopic imaging.